| Biosimilars: how can payers get long-term savings? J Mestre-Ferrandiz, A Towse, M Berdud Pharmacoeconomics 34 (6), 609-616, 2016 | 104 | 2016 |
| Incentives and intrinsic motivation in healthcare M Berdud, JM Cabasés, J Nieto Gaceta sanitaria 30 (6), 408-414, 2016 | 89 | 2016 |
| Establishing a reasonable price for an orphan drug M Berdud, M Drummond, A Towse Cost Effectiveness and Resource Allocation 18 (1), 1-18, 2020 | 69 | 2020 |
| The future of global health procurement: Issues around pricing transparency M Berdud, K Chalkidou, EB Dean, J Ferraro, L Garrison, C Nemzoff, ... Center for Global Development 50 (7), 27-31, 2019 | 13 | 2019 |
| R&D, competition and diffusion of innovation in the EU: the case of Hepatitis C M Berdud, M Garau, M Neri, P O’Neill, C Sampson, A Towse OHE research paper 18 (06), 2018 | 9 | 2018 |
| What do pharmaceuticals really cost in the long run D Lakdawalla, JP MacEwan, R Dubois, K Westrich, M Berdud, A Towse Am J Manag Care 23 (8), 488-493, 2017 | 9 | 2017 |
| Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria M Berdud, A Towse, H Kettler Oxford Review of Economic Policy 32 (1), 64-87, 2016 | 6 | 2016 |
| Study of the potential use of an EU Transferable Exclusivity Extension (TEE) to incentivize antibiotic R&D M Berdud, J Ferraro, J Mestre-Ferrandiz, A Towse FINAL REPORT—DECEMBER, 2019 | 5 | 2019 |
| PNS99 A THEORY ON ICER PRICING AND OPTIMAL LEVEL OF COST-EFFECTIVENESS THRESHOLD M Berdud, J Ferraro, A Towse Value in Health 23, S301-S302, 2020 | 4 | 2020 |
| Motivational capital and incentives in health care organizations M Berdud, JM Cabasés Hita, J Nieto Vázquez | 4 | 2014 |
| Identity, incentives and motivational capital in public organizations M Berdud, JM Cabasés Hita, J Nieto Vázquez | 3 | 2014 |
| The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom M Berdud, N Wallin-Bernhardsson, B Zamora, P Lindgren, A Towse Value in Health 26 (3), 328-335, 2023 | 2 | 2023 |
| Building Cost-Effectiveness Thresholds for the Future D Kourouklis, C Sampson, M Berdud, C Skedgel Signal, 08, 2022 | 2 | 2022 |
| Incentivos y motivación intrínseca en la sanidad M Berdud, JM Cabasés, J Nieto Gaceta Sanitaria 30 (6), 408-414, 2016 | 2 | 2016 |
| Intrinsic motivation, incentives and motivational capital in health care organizations. Universidad Pública de Navarra M Berdud, JM Cabasés, J Nieto Department of Economics Working Paper Series, 2014 | 2 | 2014 |
| Incentives beyond the money and motivational capital in health care organizations M Berdud, JM Cabasés Hita | 2 | 2012 |
| A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold M Berdud, J Ferraro, A Towse Office of Health Economics, 2020 | 1 | 2020 |
| Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market F Maignen, M Berdud, G Hampson, P Lorgelly Office of Health Economics Nov, 2017 | 1 | 2017 |
| 'Macro'Evaluation of the NIHR Oxford Biomedical Research Centre G Hampson, C Lichten, M Berdud, A Pollitt, J Mestre-Ferrandiz, J Sussex, ... Office of Health Economics Research Papers, 2017 | 1 | 2017 |
| Biosimilars: achieving long-term savings and competitive markets J Mestre-Ferrandiz, A Towse, M Berdud Generics and Biosimilars Initiative Journal 5 (3), 103-106, 2016 | 1 | 2016 |
